20/20 BioLabs reports Q2 2026 results; cancer test revenue hits record
20/20 BioLabs (AIDX) reports its second quarter 2026 financial results and notes recent operational progress, stating cancer test revenue reaches a record quarterly level.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.